Bonnie Vlahos Selected Research

Etanercept (Enbrel)

3/2024	Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies.
2/2024	Erosions on T1-Weighted Magnetic Resonance Imaging Versus Radiography of Sacroiliac Joints in Recent-Onset Axial Spondyloarthritis: 2-Year Data (EMBARK Trial and DESIR Cohort).
5/2023	Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
1/2023	Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial.
1/2021	Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR.
1/2021	Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis.
1/2020	Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study.
1/2020	Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis.
1/2019	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
1/2019	Clinical Improvements as Predictors of Improvements in Patient-Reported Outcomes: Post Hoc Analysis of a Randomized, Open-Label Study of Etanercept in Latin American Patients with Rheumatoid Arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bonnie Vlahos Research Topics

Disease

19	Rheumatoid Arthritis 01/2021 - 04/2012
10	Axial Spondyloarthritis 03/2024 - 08/2014
7	Atopic Dermatitis (Atopic Eczema) 03/2024 - 11/2019
6	Inflammation (Inflammations) 05/2024 - 08/2014
6	Arthritis (Polyarthritis) 05/2023 - 06/2011
6	Non-Radiographic Axial Spondyloarthritis 01/2023 - 10/2015
6	Ankylosing Spondylitis 01/2023 - 06/2011
4	Psoriatic Arthritis 05/2023 - 06/2014
4	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 05/2023 - 06/2014
3	Pruritus (Itching) 07/2023 - 11/2019
2	Sacroiliitis 01/2023 - 08/2014
2	Pain (Aches) 01/2021 - 04/2012
2	Back Pain (Backache) 12/2018 - 01/2016
2	Infections 01/2016 - 01/2014
1	Spondylarthropathies 05/2024
1	Hodgkin Disease (Hodgkin's Disease) 05/2023
1	Neoplasms (Cancer) 05/2023
1	Tuberculosis (Tuberculoses) 05/2023
1	Eczema 04/2020
1	Hyperplasia 11/2019
1	Necrosis 01/2018
1	Low Back Pain (Lumbago) 01/2016
1	Chronic Disease (Chronic Diseases) 01/2013
1	Fatigue 01/2013

Drug/Important Bio-Agent (IBA)

34	Etanercept (Enbrel)FDA Link 03/2024 - 06/2011
11	Methotrexate (Mexate)FDA LinkGeneric 05/2023 - 01/2013
8	Antirheumatic Agents (DMARD)IBA 09/2018 - 04/2012
6	crisaboroleIBA 03/2024 - 11/2019
5	Ointments (Pastes)IBA 01/2024 - 11/2019
5	C-Reactive ProteinIBA 01/2023 - 08/2014
4	Phosphodiesterase 4 InhibitorsIBA 01/2024 - 11/2019
3	Sulfasalazine (Azulfidine)FDA LinkGeneric 03/2024 - 06/2011
3	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 01/2017
3	Adalimumab (Humira)FDA Link 01/2020 - 01/2017
3	Infliximab (Remicade)FDA Link 01/2020 - 01/2017
2	ametantrone (HAQ)IBA 01/2021 - 01/2013
2	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 12/2018 - 01/2016
2	AntibodiesIBA 01/2017 - 01/2017
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 10/2015 - 08/2014
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2012 - 06/2011
1	amsonic acid (DAS)IBA 01/2024
1	Prostaglandins AIBA 01/2021
1	Certolizumab Pegol FDA Link 01/2020
1	golimumab FDA Link 01/2020
1	Biomarkers (Surrogate Marker)IBA 11/2019
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 11/2019
1	Janus Kinase InhibitorsIBA 04/2015
1	tofacitinibIBA 04/2015
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 08/2014
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2013
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 06/2011

Therapy/Procedure

13	Therapeutics 07/2023 - 06/2011
2	Aftercare (After-Treatment) 03/2024 - 03/2013
1	Retreatment 01/2023
1	Secondary Prevention 09/2018
1	Activities of Daily Living (ADL) 01/2017